{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T23:38:44Z","timestamp":1775518724989,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jcf.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T02:10:42Z","timestamp":1678068642000},"page":"188-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A year in review (2022): Modulators and COVID19, the story goes on\u2026"],"prefix":"10.1016","volume":"22","author":[{"given":"Stefanie","family":"Dillenhoefer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3423-3158","authenticated-orcid":false,"given":"Dorothy","family":"Grogono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2707-3037","authenticated-orcid":false,"given":"Ana","family":"Morales-Tirado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.03.001_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.958658","article-title":"Risk factors for severe COVID-19 in people with cystic fibrosis: a systematic review","volume":"10","author":"Terlizzi","year":"2022","journal-title":"Front Pediatr"},{"issue":"4","key":"10.1016\/j.jcf.2023.03.001_bib0002","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.jcf.2022.06.006","article-title":"Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study","volume":"21","author":"Carr","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"11","key":"10.1016\/j.jcf.2023.03.001_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112771","article-title":"Impact of COVID-19 on lung disease in people with cystic fibrosis: a 6-month follow-up study on respiratory outcomes","volume":"10","author":"Medino","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.jcf.2023.03.001_bib0004","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1513\/AnnalsATS.202105-532OC","article-title":"Changes in care during the COVID-19 pandemic for people with cystic fibrosis","volume":"19","author":"Sanders","year":"2022","journal-title":"Ann Am Thoracic Soc"},{"key":"10.1016\/j.jcf.2023.03.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(22)00739-1","article-title":"Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic","author":"Doumit","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"key":"10.1016\/j.jcf.2023.03.001_bib0006","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","author":"Southern","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"3","key":"10.1016\/j.jcf.2023.03.001_bib0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respirat Med"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.001_bib0008","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.001_bib0009","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.03.001_bib0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.03.001_bib0011","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.001_bib0012","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"2","key":"10.1016\/j.jcf.2023.03.001_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jcf.2021.07.017","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor in liver transplant patients with cystic fibrosis","volume":"21","author":"McKinzie","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.001_bib0014","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis","volume":"21","author":"Shakir","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"key":"10.1016\/j.jcf.2023.03.001_bib0015","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI","author":"Schwarzenberg","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"6","key":"10.1016\/j.jcf.2023.03.001_bib0016","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"6","key":"10.1016\/j.jcf.2023.03.001_bib0017","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"4","key":"10.1016\/j.jcf.2023.03.001_bib0018","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"key":"10.1016\/j.jcf.2023.03.001_bib0019","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","author":"Mayer-Hamblett","year":"2022","journal-title":"Lancet Respirat Med"},{"issue":"11","key":"10.1016\/j.jcf.2023.03.001_bib0020","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and Safety of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2023.03.001_bib0021","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcf.2022.02.003","article-title":"A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor\/ivacaftor in children \u2265 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant","volume":"21","author":"Sawicki","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"10","key":"10.1016\/j.jcf.2023.03.001_bib0022","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A Phase 3, Open-Label Study of Lumacaftor\/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.03.001_bib0023","article-title":"VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations","author":"Simmonds","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"4","key":"10.1016\/j.jcf.2023.03.001_bib0024","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jcf.2021.11.009","article-title":"Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation","volume":"21","author":"Sanders","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.001_bib0025","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jcf.2022.04.006","article-title":"Antipseudomonal treatment decisions during CF exacerbation management","volume":"21","author":"VanDevanter","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.001_bib0026","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcf.2022.05.010","article-title":"The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations","volume":"21","author":"Zikic","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.001_bib0027","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/thoraxjnl-2021-217594","article-title":"Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial","volume":"77","author":"Wildman","year":"2022","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jcf.2023.03.001_bib0028","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jcf.2022.04.014","article-title":"Association between early respiratory viral infections and structural lung disease in infants with cystic fibrosis","volume":"21","author":"Sanders","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"8","key":"10.1016\/j.jcf.2023.03.001_bib0029","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-2600(22)00165-5","article-title":"The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial","volume":"10","author":"Stick","year":"2022","journal-title":"Lancet Respirat Med"},{"issue":"7","key":"10.1016\/j.jcf.2023.03.001_bib0030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S2213-2600(21)00546-4","article-title":"The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial","volume":"10","author":"Tiddens","year":"2022","journal-title":"Lancet Respirat Med"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.001_bib0031","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"issue":"2","key":"10.1016\/j.jcf.2023.03.001_bib0032","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"},{"key":"10.1016\/j.jcf.2023.03.001_bib0033","article-title":"Development of novel therapeutics for all individuals with CF (the future goes on)","author":"Amaral","year":"2022","journal-title":"J Cystic Fibrosis: Off J Eur Cystic Fibrosis Soc"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:49:26Z","timestamp":1761601766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1569199323000656"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A year in review (2022): Modulators and COVID19, the story goes on\u2026","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}